Literature DB >> 7656280

Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat.

L A Brown1, D J Nunez, C I Brookes, M R Wilkins.   

Abstract

OBJECTIVE: At present little is known about the factors that regulate the expression of the endothelins and their receptors in cardiac tissue in vivo. The aim of this study was to investigate changes in expression of the endothelins (ET-1, ET-2, and ET-3) and their receptors (ETAR and ETBR) in the hypertrophied heart of the aortovenocaval (AV) fistula rat.
METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify cardiac mRNA expression of the endothelins and their receptors during the development of cardiac hypertrophy, while radioligand binding was employed to quantify the amount of [125I]-ET-1 binding to cardiac membranes. Tissue and plasma concentrations of ET-1 were measured by radioimmunoassay.
RESULTS: In control sham operated animals, ET-1 mRNA was approximately fivefold greater in atria than in ventricles (P < 0.05), but there were no atrioventricular differences in ET-2 or ET-3 mRNA. In the AV fistula rats there was a prompt three- to fourfold increase in ET-1 mRNA in atria and a progressive five- to sevenfold rise in ventricles during cardiac hypertrophy. There were no changes in ET-2 or ET-3 transcript prevalences, except for a late rise (35 d) in ET-2 mRNA levels in left ventricle. Consistent with ET-1 mRNA measurements, immunoreactive endothelin levels were increased by 7 d in atria, but not in ventricles. In control rat hearts, ETAR mRNA levels were similar in atria and ventricles, but the prevalence of ETBR was approximately sevenfold greater in the former. ETAR mRNA prevalence increased with hypertrophy in all chambers, while ETBR transcript levels were raised only in the right ventricle. There was no significant difference in [125I]-ET-1 binding between atrial samples from 35 d control and 35 d AV fistula rats, suggesting rapid turnover of endothelin receptors balanced by increased transcription from the ETAR gene.
CONCLUSIONS: During cardiac hypertrophy in AV fistula rats there is increased activity of the endothelin system mediated principally by ET-1 and the ETAR subtype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656280

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  6 in total

Review 1.  Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

Authors:  Scott P Levick; Giselle C Meléndez; Eric Plante; Jennifer L McLarty; Gregory L Brower; Joseph S Janicki
Journal:  Cardiovasc Res       Date:  2010-08-24       Impact factor: 10.787

2.  Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung.

Authors:  L Zhao; R al-Tubuly; A Sebkhi; A A Owji; D J Nunez; M R Wilkins
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 3.  Myofilament dysfunction as an emerging mechanism of volume overload heart failure.

Authors:  Kristin Wilson; Pamela A Lucchesi
Journal:  Pflugers Arch       Date:  2014-02-01       Impact factor: 3.657

Review 4.  Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.

Authors:  Zaid Abassi; Ilia Goltsman; Tony Karram; Joseph Winaver; Aaron Hoffman
Journal:  J Biomed Biotechnol       Date:  2011-01-11

5.  Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors.

Authors:  Caroline R Archer; Emma L Robinson; Faye M Drawnel; H Llewelyn Roderick
Journal:  Cell Signal       Date:  2017-04-13       Impact factor: 4.315

6.  Involvement of Cytokines in the Pathogenesis of Salt and Water Imbalance in Congestive Heart Failure.

Authors:  Zaher S Azzam; Safa Kinaneh; Fadel Bahouth; Reem Ismael-Badarneh; Emad Khoury; Zaid Abassi
Journal:  Front Immunol       Date:  2017-06-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.